Oporia Osteoporosis NDA Review Extended To September
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's review of Pfizer's selective estrogen receptor modulator Oporia (lasofoxifene) for the treatment of osteoporosis has been extended until September
You may also be interested in...
Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.